Ondek Announces Appointment of Chief Executive Officer
News Mar 19, 2013
Australian drug delivery system company Ondek Limited has announced the appointment of Dr Jenny Harry as Chief Executive Officer.
Ondek is developing innovative ways to deliver medical therapies using the discoveries of Australian Nobel Laureate Barry Marshall.
The Company is currently working to use the stomach bacteria that helped win Dr Marshall the top prize in medicine to fight childhood asthma and allergies.
Ondek Chairman Peter Hammond said, “Dr Harry will play a key role in the global commercialization of Ondek’s novel drug delivery technology. She has already had a significant and positive impact on the business and her experience and skills will be invaluable as we progress through the clinic and negotiate commercial alliances.”
Dr Harry is an experienced CEO of global biotechnology businesses. Before joining Ondek she served as CEO and Managing Director of Tyrian Diagnostics Limited (ASX: TDX) where she led the transformation of the Company from research and development to diagnostics and oversaw commercialization of its first diagnostic products.
She has experience in leading high performing teams, strategic planning and portfolio development, structuring and negotiating agreements with multi-nationals, raising capital for early stage biotechnology companies and investor relations.
Dr Harry has a PhD in developmental biology from Macquarie University, and is a graduate of the Harvard Business School General Manager Program and the Australian Institute of Company Directors. Dr Harry is based in Sydney at the offices of Exto Partners Pty Ltd.
Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain CancerNews
Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.READ MORE
XenoGesis and Juniper Pharma Services Strengthen AllianceNews
Campanies extend strategic alliance in early drug development services.READ MORE
Quotient Clinical Signs Cocrystal Agreement with NuformixNews
Partnership to evaluate cocrystal formulations using translational pharmaceutics.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018